| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adverse events associated with aprepitant pediatric bone cancer patients
|
Okumura, Lucas M
|
|
2019
|
25 |
3 |
p. 735-738
|
article
|
| 2 |
Aplastic anemia secondary to propylthiouracil: A rare and life-threatening adverse effect
|
Shaikh, Hira
|
|
2019
|
25 |
3 |
p. 715-718
|
article
|
| 3 |
A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia
|
Johannesmeyer, Herman J
|
|
2019
|
25 |
3 |
p. 535-543
|
article
|
| 4 |
Can clinical pharmacists bridge a gap between medical oncologists and patients in resource-limited oncology settings? An experience in Nepal
|
Shrestha, Sunil
|
|
2019
|
25 |
3 |
p. 765-768
|
article
|
| 5 |
Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib
|
Hermel, David J
|
|
2019
|
25 |
3 |
p. 699-702
|
article
|
| 6 |
Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists
|
Bryk, Amy
|
|
2019
|
25 |
3 |
p. 558-566
|
article
|
| 7 |
Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy
|
Tieu, Jennifer D
|
|
2019
|
25 |
3 |
p. 520-528
|
article
|
| 8 |
Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors
|
Williams, Kiersten J
|
|
2019
|
25 |
3 |
p. 544-550
|
article
|
| 9 |
Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma
|
Lubcke, Nicole
|
|
2019
|
25 |
3 |
p. 724-726
|
article
|
| 10 |
Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia
|
Stankowicz, Matthew
|
|
2019
|
25 |
3 |
p. 710-714
|
article
|
| 11 |
Dasatinib-induced pulmonary arterial hypertension – A rare late complication
|
Ibrahim, Uroosa
|
|
2019
|
25 |
3 |
p. 727-730
|
article
|
| 12 |
Developing recommendations for the safe handling of oral anti-cancer drugs in community pharmacies: A pan-Canadian consensus approach
|
Vu, Kathy
|
|
2019
|
25 |
3 |
p. 674-688
|
article
|
| 13 |
Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study
|
Mukherjee, Sarbajit
|
|
2019
|
25 |
3 |
p. 762-764
|
article
|
| 14 |
Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab
|
McAlister, Renee K
|
|
2019
|
25 |
3 |
p. 706-709
|
article
|
| 15 |
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports
|
Gilreath, Jeffrey A
|
|
2019
|
25 |
3 |
p. 719-723
|
article
|
| 16 |
Implementation of additional prescribing authorization among oncology pharmacists in Alberta
|
Au, Bianca
|
|
2019
|
25 |
3 |
p. 584-598
|
article
|
| 17 |
Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin
|
Osorio, S
|
|
2019
|
25 |
3 |
p. 694-698
|
article
|
| 18 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review
|
Bozkaya, Yakup
|
|
2019
|
25 |
3 |
p. 754-757
|
article
|
| 19 |
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
|
Moore, Donald C
|
|
2019
|
25 |
3 |
p. 613-622
|
article
|
| 20 |
Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks
|
Yerram, Prakirthi
|
|
2019
|
25 |
3 |
p. 529-534
|
article
|
| 21 |
Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia
|
DasGupta, Ryan K
|
|
2019
|
25 |
3 |
p. 567-576
|
article
|
| 22 |
Integration of clinical pharmacists into an ambulatory, pediatric hematology/oncology/transplant clinic
|
Defoe, Kimberly D
|
|
2019
|
25 |
3 |
p. 607-612
|
article
|
| 23 |
Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report
|
Rodriguez-Reyes, Montserrat
|
|
2019
|
25 |
3 |
p. 739-742
|
article
|
| 24 |
Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients
|
Lee, Pauline
|
|
2019
|
25 |
3 |
p. 758-761
|
article
|
| 25 |
Nonallergic cutaneous pigmentation is commonly observed after methotrexate administration
|
Ikawa, Yasuhiro
|
|
2019
|
25 |
3 |
p. 769-771
|
article
|
| 26 |
Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases
|
Thomas, Christan M
|
|
2019
|
25 |
3 |
p. 623-637
|
article
|
| 27 |
Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: Complications, treatments, and the emerging role of memantine
|
Lynch, Meghan
|
|
2019
|
25 |
3 |
p. 657-662
|
article
|
| 28 |
Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities
|
Rausch, Caitlin R
|
|
2019
|
25 |
3 |
p. 747-753
|
article
|
| 29 |
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report
|
Ettleson, Matthew
|
|
2019
|
25 |
3 |
p. 731-734
|
article
|
| 30 |
Systemic anticancer therapy in the last 30 days of life: Retrospective audit from an Australian Regional Cancer Centre
|
Gilbar, Peter J
|
|
2019
|
25 |
3 |
p. 599-606
|
article
|
| 31 |
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
|
Dasanu, Constantin A
|
|
2019
|
25 |
3 |
p. 638-647
|
article
|
| 32 |
Thank you to Reviewers
|
|
|
2019
|
25 |
3 |
p. 519
|
article
|
| 33 |
The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer
|
Wasko, Justin A
|
|
2019
|
25 |
3 |
p. 703-705
|
article
|
| 34 |
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome
|
Boutin, Alyssa
|
|
2019
|
25 |
3 |
p. 577-583
|
article
|
| 35 |
Thiotepa-induced cutaneous toxicity in pediatric patients: Case report and implementation of preventive care guidelines
|
Van Schandevyl, Guy
|
|
2019
|
25 |
3 |
p. 689-693
|
article
|
| 36 |
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
|
Stroud, Chipman RG
|
|
2019
|
25 |
3 |
p. 551-557
|
article
|
| 37 |
To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade
|
Chung, Clement
|
|
2019
|
25 |
3 |
p. 663-673
|
article
|
| 38 |
Updates and novel treatments in urothelial carcinoma
|
Hanna, Kirollos S
|
|
2019
|
25 |
3 |
p. 648-656
|
article
|
| 39 |
Verapamil as a culprit of palbociclib toxicity
|
Gowarty, Jasmine L
|
|
2019
|
25 |
3 |
p. 743-746
|
article
|
Journal description